BillionToOne, Inc. Class A Common Stock (BLLN)vsEli Lilly and Company (LLY)
BLLN
BillionToOne, Inc. Class A Common Stock
$75.05
+1.82%
HEALTHCARE · Cap: $3.90B
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 21262% more annual revenue ($65.18B vs $305.11M). LLY leads profitability with a 31.7% profit margin vs 1.0%. LLY trades at a lower P/E of 37.0x. LLY earns a higher WallStSmart Score of 78/100 (B+).
BLLN
Avoid34
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 113.1% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
0.0% earnings growth
ROE of 2.3% — below average capital efficiency
1.0% margin — thin
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth. Revenue growth of 113.1% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : BLLN
The primary concerns for BLLN are EPS Growth, Return on Equity, Profit Margin. A P/E of 605.3x leaves little room for execution misses. Thin 1.0% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
BLLN profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
BLLN is growing revenue faster at 113.1% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 34/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?